Adaptogenics Health Corp. (CSE: ADPT), a Vancouver-based company focused on peptide therapeutics and pharmaceutical-quality supply, has announced the engagement of InvestorBrandNetwork (IBN) to support its corporate communications strategy. Under the agreement, IBN will leverage its distribution network to raise awareness of Adaptogenics among investors, journalists, and the broader public. The deal carries a defined financial commitment, and investors may be watching to see how increased visibility translates into broader market awareness for the company's peptide and nutraceutical programmes.

Key Points

  • Adaptogenics Health Corp. (CSE: ADPT) is a Vancouver-based peptide therapeutics and pharmaceutical-quality supply company
  • The company has engaged InvestorBrandNetwork (IBN) to expand corporate communications and investor outreach
  • IBN will be compensated US$4,000 per month for an initial one-year term totalling US$48,000, with no securities issued as compensation
  • Investors may watch for increased market awareness as IBN's distribution network reaches syndication outlets, newsletters, and social media channels

IBN Engagement Terms and Compensation Structure

Adaptogenics has entered a one-year agreement with IBN at a monthly fee of US$4,000, amounting to US$48,000 for the initial term. Following the initial period, the release states the agreement will continue on a quarter-to-quarter basis unless terminated by either party. The company confirmed that no securities have been or will be issued to IBN or its principals as compensation. IBN is described as an arm's-length service provider with no direct or indirect interest in the securities of Adaptogenics, underscoring the independence of the arrangement.

IBN's Distribution Reach and Communications Strategy for ADPT

IBN will deploy its investor-focused network, which the announcement describes as encompassing over 5,000 syndication outlets, newsletters, social media channels, and wire services via InvestorWire. The firm reports a collective audience of millions of social media followers and claims more than 20 years of experience serving over 500 client partners across a family of 75-plus trusted brands. Adaptogenics intends to use this reach to connect with a wider audience of investors and journalists as it advances its peptide therapeutics and nutraceutical business lines.

Adaptogenics' Focus on Peptide Therapeutics and GLP-1 Companion Products

The company describes itself as science-led, focused on identifying, acquiring, designing, and advancing proprietary peptide and small molecule programmes across metabolic health, muscle preservation, mitochondrial biology, and inflammation. Adaptogenics states it will continue existing nutraceutical operations while evaluating GLP-1 companion products intended to address challenges associated with medical weight loss, including muscle loss, nutritional deficiencies, and reduced physical function. The immediate share price impact of the IBN engagement was not clear from available public information.